Page last updated: 2024-10-23

bisbenzimidazole and Barrett Esophagus

bisbenzimidazole has been researched along with Barrett Esophagus in 1 studies

Bisbenzimidazole: A benzimidazole antifilarial agent; it is fluorescent when it binds to certain nucleotides in DNA, thus providing a tool for the study of DNA replication; it also interferes with mitosis.

Barrett Esophagus: A condition with damage to the lining of the lower ESOPHAGUS resulting from chronic acid reflux (ESOPHAGITIS, REFLUX). Through the process of metaplasia, the squamous cells are replaced by a columnar epithelium with cells resembling those of the INTESTINE or the salmon-pink mucosa of the STOMACH. Barrett's columnar epithelium is a marker for severe reflux and precursor to ADENOCARCINOMA of the esophagus.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Takashima, T1
Fujiwara, Y1
Hamaguchi, M1
Sasaki, E1
Tominaga, K1
Watanabe, T1
Oshitani, N1
Higuchi, K1
Arakawa, T1

Other Studies

1 other study available for bisbenzimidazole and Barrett Esophagus

ArticleYear
Relationship between peroxisome proliferator-activated receptor-gamma expression and differentiation of human esophageal squamous cell carcinoma.
    Oncology reports, 2005, Volume: 13, Issue:4

    Topics: Antibodies, Monoclonal; Apoptosis; Barrett Esophagus; Biopsy; Bisbenzimidazole; Blotting, Western; C

2005